354 filings
8-K
OTLC
Oncotelic Therapeutics, Inc.
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
OTLC
Oncotelic Therapeutics, Inc.
30 Oct 23
Entry into a Material Definitive Agreement
9:00am
8-K
OTLC
Oncotelic Therapeutics, Inc.
23 Aug 23
Regulation FD Disclosure
10:30am
8-K
OTLC
Oncotelic Therapeutics, Inc.
13 Jul 23
Entry into a Material Definitive Agreement
12:00am
8-K
OTLC
Oncotelic Therapeutics, Inc.
19 May 23
Amendments to Articles of Incorporation or Bylaws
4:45pm
8-K
mqe9rsz9i
13 Mar 23
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
9:00am
8-K
wrxb8b0n s4naedq1v
2 Mar 23
Departure of Directors or Certain Officers
9:00am
8-K
lseidnh5t6ub38 7f
3 Jan 23
Oncotelic Issues Year End Message to Shareholders
7:00am
8-K
b18yluhr63
20 Dec 22
Regulation FD Disclosure
7:45am
8-K
re8iarezkandzix
15 Jul 22
Regulation FD Disclosure
7:00am
8-K
2wl2iifw5mwuc0u1
27 Jun 22
Entry into a Material Definitive Agreement
5:25pm
8-K
0cy ncpku
22 Jun 22
Regulation FD Disclosure
8:46am
8-K
0caj2bkujza
3 Jun 22
Entry into a Material Definitive Agreement
4:46pm
8-K
rzk3wx2nfejdrj2j xn
6 May 22
Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer
6:10am
8-K
5ezterc
13 Apr 22
Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited
11:56am
8-K
vistdja det
6 Apr 22
Oncotelic and Dragon Overseas Capital Limited Completed Joint Venture Transaction
9:16am
8-K
t7tn0o
4 Apr 22
Entry into a Material Definitive Agreement
5:26pm
8-K
brwas
1 Apr 22
Regulation FD Disclosure
9:15am
8-K
holpvfmsgylzn9
17 Feb 22
Other Events
9:00am
8-K
kaox6amuo27wb
15 Feb 22
Entry into a Material Definitive Agreement
5:25pm